Biblioteca CRAI Dulce Chacón - Universidad Europea de Madrid

CRAI Library - Madrid
Your cart is empty.
My folder ( items) | My account
Image from Google Jackets

Advances in biology and treatment of glioblastoma / Kumaravel Somasundaram, editor.

Contributor(s): Somasundaram, Kumaravel,, editor literario
Material type: materialTypeLabelE-bookSeries: (Current cancer research).Publisher: Cham : Springer, 2017Description: 1 recurso en línea (272 páginas).ISBN: 3319568205; 9783319568201.Subject: Glioma | Sistema nervioso central -- EnfermedadesOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)Digital Resources
Contents:
Preface; Contents; Author Biography; Chapter 1: Maximal Safe Resection in Glioblastoma: Use of Adjuncts; 1.1 Introduction; 1.2 Preoperative Investigations; 1.2.1 Magnetic Resonance Imaging; 1.2.2 Functional MRI; 1.2.3 Magnetoencephalography; 1.2.4 Navigated Transcranial Magnetic Stimulation; 1.2.5 Diffusion Tensor Imaging; 1.2.6 Deformable Anatomic Templates; 1.3 Intraoperative Adjuncts; 1.3.1 Intraoperative Image Guidance Techniques; 1.3.2 5-Aminolevulinic Acid; 1.3.3 Functional Cortical and Subcortical Mapping; 1.3.4 Principles of Direct Electrical Stimulation.
1.3.5 Motor Mapping and Monitoring1.3.5.1 Somatosensory Evoked Potentials; 1.3.5.2 Motor Evoked Potentials; 1.3.5.3 Cortical Stimulation; 1.3.5.4 Subcortical Stimulation; 1.3.6 Language Mapping; 1.3.7 Resection Principles; 1.4 Conclusion; References; Chapter 2: Molecular Pathology of Glioblastoma- An Update; 2.1 Introduction to Adult Diffuse Gliomas and Glioblastoma with Emphasis on Changing Concepts; 2.2 ISN Haarlem Guidelines and Evolution of WHO 2016; 2.3 WHO 2007 Classification Versus 2016 Classification w.r.t Glioblastoma (Table 2.2).
2.4 Glioblastoma: Gross Pathology, Histomorphology and the New Definitions2.4.1 Glioblastoma, IDH-Wild Type; 2.4.2 Glioblastoma, IDH Mutant (Fig. 2.7); 2.5 Molecules That Define Glioblastoma in Detail; 2.5.1 IDH Mutations; 2.5.2 O6-Methyl Guanine DNA Methyl Transferase (MGMT) Gene Promoter Methylation; 2.5.3 ATRX Mutation; 2.5.4 TP53 Mutation; 2.5.5 TERT Promoter Mutation; 2.5.6 Cytogenetic Abnormalities; 2.5.7 EGFR Amplification and Mutation; 2.5.8 PTEN Mutation; 2.5.9 Platelet Derived Growth Factor Receptor Alpha(PDGFRA); 2.5.10 Neurofibromatosis Type 1 Gene (NF1)Inactivation.
2.5.11 Signaling Pathways Altered in Glioblastoma:2.6 Molecular Biology of Recurrence in Glioblastoma Tumors; 2.7 Summary; 2.8 Clinical Trials; 2.9 Need of the Hour; References; Chapter 3: Current Therapies and Future Directions in Treatment of Glioblastoma; 3.1 Introduction; 3.2 Newly Diagnosed Glioblastoma; 3.2.1 Surgical Resection; 3.2.2 First Line Therapy for Newly Diagnosed GBM; 3.3 Recurrent Glioblastoma; 3.4 Glioblastoma in Older Adults; 3.5 Gliomatosis Cerebrii; 3.6 Targeted Agents in Treatment of GBM; 3.6.1 EGFR Inhibitors; 3.6.2 PI3K and mTOR Inhibitors.
3.6.3 VEGF and VEGFR Inhibitors3.7 Biological Agents in Clinical Trials Against Glioblastoma; 3.7.1 Virus-Based Therapies; 3.7.2 Immunotherapies; 3.7.2.1 Immune Checkpoint Inhibitors; 3.7.2.2 Genetically Engineered T-cells; 3.8 Conclusions; References; Chapter 4: Recent Advances for Targeted Therapies in Glioblastoma; 4.1 Recent Advances for Targeted Therapies in Glioblastoma; 4.2 The Cancer Genome Atlas; 4.3 Tumor Protein P53 Signaling Pathway; 4.4 Retinoblastoma (Rb) Pathway; 4.5 Receptor Tyrosine Kinases Pathway; 4.5.1 VEGFR; 4.5.2 EGFR; 4.5.3 PDGFR; 4.5.4 PI3K/AKT/PTEN/mTOR.
Abstract: This volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma. Chapter authors are junior and senior investigators, who are well established in their particular areas and include neurosurgeons, neuropathologists, neurooncologists and basic scientists.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode Item holds
LIBRO-E NO PRÉSTAMO LIBRO-E NO PRÉSTAMO Madrid Digital Acceso Electrónico (UEM) Ciencias de la Salud RC280 .B7 2017 EB (Browse shelf(Opens below)) Acceso electrónico eBook.20023892
Total holds: 0

Includes index

SpringerLink

Preface; Contents; Author Biography; Chapter 1: Maximal Safe Resection in Glioblastoma: Use of Adjuncts; 1.1 Introduction; 1.2 Preoperative Investigations; 1.2.1 Magnetic Resonance Imaging; 1.2.2 Functional MRI; 1.2.3 Magnetoencephalography; 1.2.4 Navigated Transcranial Magnetic Stimulation; 1.2.5 Diffusion Tensor Imaging; 1.2.6 Deformable Anatomic Templates; 1.3 Intraoperative Adjuncts; 1.3.1 Intraoperative Image Guidance Techniques; 1.3.2 5-Aminolevulinic Acid; 1.3.3 Functional Cortical and Subcortical Mapping; 1.3.4 Principles of Direct Electrical Stimulation.

1.3.5 Motor Mapping and Monitoring1.3.5.1 Somatosensory Evoked Potentials; 1.3.5.2 Motor Evoked Potentials; 1.3.5.3 Cortical Stimulation; 1.3.5.4 Subcortical Stimulation; 1.3.6 Language Mapping; 1.3.7 Resection Principles; 1.4 Conclusion; References; Chapter 2: Molecular Pathology of Glioblastoma- An Update; 2.1 Introduction to Adult Diffuse Gliomas and Glioblastoma with Emphasis on Changing Concepts; 2.2 ISN Haarlem Guidelines and Evolution of WHO 2016; 2.3 WHO 2007 Classification Versus 2016 Classification w.r.t Glioblastoma (Table 2.2).

2.4 Glioblastoma: Gross Pathology, Histomorphology and the New Definitions2.4.1 Glioblastoma, IDH-Wild Type; 2.4.2 Glioblastoma, IDH Mutant (Fig. 2.7); 2.5 Molecules That Define Glioblastoma in Detail; 2.5.1 IDH Mutations; 2.5.2 O6-Methyl Guanine DNA Methyl Transferase (MGMT) Gene Promoter Methylation; 2.5.3 ATRX Mutation; 2.5.4 TP53 Mutation; 2.5.5 TERT Promoter Mutation; 2.5.6 Cytogenetic Abnormalities; 2.5.7 EGFR Amplification and Mutation; 2.5.8 PTEN Mutation; 2.5.9 Platelet Derived Growth Factor Receptor Alpha(PDGFRA); 2.5.10 Neurofibromatosis Type 1 Gene (NF1)Inactivation.

2.5.11 Signaling Pathways Altered in Glioblastoma:2.6 Molecular Biology of Recurrence in Glioblastoma Tumors; 2.7 Summary; 2.8 Clinical Trials; 2.9 Need of the Hour; References; Chapter 3: Current Therapies and Future Directions in Treatment of Glioblastoma; 3.1 Introduction; 3.2 Newly Diagnosed Glioblastoma; 3.2.1 Surgical Resection; 3.2.2 First Line Therapy for Newly Diagnosed GBM; 3.3 Recurrent Glioblastoma; 3.4 Glioblastoma in Older Adults; 3.5 Gliomatosis Cerebrii; 3.6 Targeted Agents in Treatment of GBM; 3.6.1 EGFR Inhibitors; 3.6.2 PI3K and mTOR Inhibitors.

3.6.3 VEGF and VEGFR Inhibitors3.7 Biological Agents in Clinical Trials Against Glioblastoma; 3.7.1 Virus-Based Therapies; 3.7.2 Immunotherapies; 3.7.2.1 Immune Checkpoint Inhibitors; 3.7.2.2 Genetically Engineered T-cells; 3.8 Conclusions; References; Chapter 4: Recent Advances for Targeted Therapies in Glioblastoma; 4.1 Recent Advances for Targeted Therapies in Glioblastoma; 4.2 The Cancer Genome Atlas; 4.3 Tumor Protein P53 Signaling Pathway; 4.4 Retinoblastoma (Rb) Pathway; 4.5 Receptor Tyrosine Kinases Pathway; 4.5.1 VEGFR; 4.5.2 EGFR; 4.5.3 PDGFR; 4.5.4 PI3K/AKT/PTEN/mTOR.

This volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma. Chapter authors are junior and senior investigators, who are well established in their particular areas and include neurosurgeons, neuropathologists, neurooncologists and basic scientists.

There are no comments on this title.

to post a comment.
Share